

Serial No. 09/210,952
March 21, 2003
Page 2

Please amend claim 20 as shown on the following pages.

Marked-up sheets of the claim amendments are attached to this Amendment. Inserted material is underlined and deleted material is enclosed within brackets.

C

Serial No. 09/210,952

March 21, 2003

Page 3

Clean Copy of Amended Claim 20

1 20^(Twice amended). A substantially pure conopeptide selected from the group consisting of:

- (a) PnVIIA: Asp-Cys-Thr-Ser-Xaa₁-Phe-Gly-Arg-Cys-Thr-Val-Asn-Ser-Xaa₂-Cys-Cys-Ser-Asn-Ser-Cys-Asp-Gln-Thr-Tyr-Cys-Xaa₂-Leu-Tyr-Ala-Phe-Xaa₃-Ser (SEQ ID NO:6) wherein Xaa₁ is Trp, Xaa₂ is γ -Glu, Xaa₃ is Hyp and the C-terminus has a free carboxyl group;
- (b) Tx6.4: Xaa₁-Leu-Xaa₂-Cys-Ser-Val-Xaa₁-Phe-Ser-His-Cys-Thr-Lys-Asp-Ser-Xaa₂-Cys-Cys-Ser-Asn-Ser-Cys-Asp-Gln-Thr-Tyr-Cys-Thr-Leu-Met-Xaa₃-Xaa₃-Asp-Xaa₁ (SEQ ID NO:7) wherein Xaa₁ is Trp, Xaa₂ is γ -Glu, Xaa₃ is Hyp and the C-terminus has a free carboxyl group;
- (c) Tx6.9: Xaa₁-Xaa₁-Arg-Xaa₁-Gly-Gly-Cys-Met-Ala-Xaa₁-Phe-Gly-Leu-Cys-Ser-Arg-Asp-Ser-Xaa₂-Cys-Cys-Ser-Asn-Ser-Cys-Asp-Val-Thr-Arg-Cys-Xaa₂-Leu-Met-Xaa₃-Phe-Xaa₃-Xaa₃-Asp-Xaa₁ (SEQ ID NO:8) wherein Xaa₁ is Trp, Xaa₂ is γ -Glu, Xaa₃ is Hyp and the C-terminus has a free carboxyl group;
- (d) Tx6.6: Asp-Xaa₁-Xaa₁-Asp-Asp-Gly-Cys-Ser-Val-Xaa₁-Gly-Xaa₃-Cys-Thr-Val-Asn-Ala-Xaa₂-Cys-Cys-Ser-Gly-Asp-Cys-His-Xaa₂-Thr-Cys-Ile-Phe-Gly-Xaa₁-Xaa₂-Val (SEQ ID NO:10) wherein Xaa₁ is Trp, Xaa₂ is γ -Glu, Xaa₃ is Hyp and the C-terminus has a free carboxyl group;
- (e) Tx6.5: Gly-Met-Xaa₁-Gly-Xaa₂-Cys-Lys-Asp-Gly-Leu-Thr-Thr-Cys-Leu-Ala-Xaa₃-Ser-Xaa₂-Cys-Cys-Ser-Xaa₂-Asp-Cys-Xaa₁-Gly-Ser-Cys-Thr-Met-Xaa₁ (SEQ ID NO:11) wherein Xaa₁ is Trp, Xaa₂ is γ -Glu, Xaa₃ is Hyp and the C-terminus has a free carboxyl group.
- (f) Gm6.7: Xaa₂-Cys-Arg-Ala-Xaa₁-Tyr-Ala-Xaa₃-Cys-Ser-Xaa₃-Gly-Ala-Gln-Cys-Cys-Ser-Leu-Leu-Met-Cys-Ser-Lys-Ala-Thr-Ser-Arg-Cys-Ile-Leu-Ala-Leu (SEQ ID NO:12) wherein Xaa₁ is Trp, Xaa₂ is γ -Glu, Xaa₃ is Hyp and the C-terminus has a free carboxyl group;
- (g) Mr6.1: Asn-Gly-Gln-Cys-Xaa₂-Asp-Val-Xaa₁-Met-Xaa₃-Cys-Thr-Ser-Asn-Xaa₁-Xaa₂-Cys-Cys-Ser-Leu-Asp-Cys-Xaa₂-Met-Tyr-Cys-Thr-Gln-Ile (SEQ ID

Serial No. 09/210,952

March 21, 2003

Page 4

NO:13) wherein Xaa₁ is Trp, Xaa₂ is γ -Glu, Xaa₃ is Hyp and the C-terminus is amidated;

(g)

(i) Mr6.2: Cys-Gly-Gly-Xaa₁-Ser-Thr-Tyr-Cys-Xaa₂-Val-Asp-Xaa₂-Xaa₂-Cys-Cys-Ser-Xaa₂-Ser-Cys-Val-Arg-Ser-Tyr-Cys-Thr-Leu-Phe (SEQ ID NO:14) wherein

(h)

Xaa₁ is Trp, Xaa₂ is γ -Glu and the C-terminus is amidated; and
(j) Mr6.3: Asn-Gly-Gly-Cys-Lys-Ala-Thr-Xaa₁-Met-Ser-Cys-Ser-Ser-Gly-Xaa₁-Xaa₂-Cys-Cys-Ser-Met-Ser-Cys-Asp-Met-Try-Cys (SEQ ID NO:15) wherein Xaa₁ is Trp, Xaa₂ is γ -Glu and the C-terminus is amidated.

CONT